The stock of Jaguar Health Inc (NASDAQ: JAGX) rose by a margin of 4.52% to finally settle at $1.85.This company’s subsidiary, known as Napo Pharmaceuticals Inc, is pleased to bolster its management team by appointing Darlene Horton to the position of Chief Medical Officer (CMO). The new official happens to be a top clinical development expert and biopharmaceutical veteran.
The acting Chief Scientific Officer of Napo Pravin Chaturvedi is excited about the new appointment. He says that their company has a lot to gain from the leader’s strong clinical experience. He also talks about Darlene’s operational leadership and her longstanding industry experience.
Chaturvedi discloses details about the subsidiary’s ongoing phase 3 clinical trial, outlining that the incoming official will help them achieve success in the trial. The study focuses on the treatment of cancer among adults.
Napo considered the official’s strong background in drug development in appointing him for the leading position. It also has immense trust in her stewardship, outlining that she will play a significant role in helping them succeed in the augmentation of their ongoing clinical studies for CTD and other diverse indications underway.
Dr. Horton has spent about 25 years focusing on clinical research and development, and her experience will enable the company to develop outstanding products and earn higher revenues.
Jaguar Health and the Italy-based Dragon SPAC Milan have provided details about a recent funding initiative. They focused on the Dragon SPAC’s initial funding, although they provided the other important details linked to the deal. For example, they disclosed that Dragon SPAC had settled for Napo EU as its target.
Napo Pharmaceuticals and Dragon SPAC move into a new progressive partnership. The terms of the deal provide that Dragon SPAC will channel some of its units to the partner. The deal with Napo Pharma involves a US$10.8 million cash placement. It is a private cash placement, and all conditions must be met. The shareholders stare at a contemplated business combination, and they need to be decisive on how they undertake the trading undertakings.